Nov 17 (Reuters) - DeCODE Genetics Inc (DCGN), a Reykjavik, Iceland-headquartered bio-pharmaceutical company filed for Chapter 11 bankruptcy protection, court documents showed.
In a filing with the U.S. Bankruptcy Court for the District of Delaware late on Monday, deCODE listed estimated total assets in the range of $50 million to $100 million and estimated total liabilities in the range of $100 million to $500 million.‹
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”